EditorialMaterial ISI SCOPUS
FRONTIERS IN PHARMACOLOGY  (2018)

Commentary: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy

Duran, J; Estrada, M

Keywords: skeletal muscle, bimagrumab, ActRIIA/B receptors, anabolic steroids, myostatin/activin

Más información

Título según WOS: Commentary: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy
Título según SCOPUS: Commentary: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy
Título de la Revista: FRONTIERS IN PHARMACOLOGY
Volumen: 9
Editorial: FRONTIERS MEDIA SA
Fecha de publicación: 2018
Idioma: English
DOI:

10.3389/fphar.2018.00381
Notas: ISI, SCOPUS